stockrow
Saturday 7 November 2026
Export KLRA’s income statement to Excel — free account
Kailera Therapeutics, Inc.
KLRA Healthcare Biotechnology
- EPS
- +100.0%
- Free cash flow
- −326.0%
Quarter to September 2026, against a year earlier
12.97
0.80
+6.57%
Follow KLRA
Alert me
| Dec '25 | Dec '24 | |
|---|---|---|
Current Ratio |
12.01 | 25.70 |
Net Debt/EBITDA |
3.46 | 0.00 |
Debt/Assets |
0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 |
Asset Turnover |
0.00 | — |
Operating CF/Net income |
0.81 | 0.00 |
Capex/Depreciation |
(6.74) | 0.00 |
| 51.79% | — | |
| (34.21%) | — | |
ROIC |
(110.14%) | 0.00% |
Return on Tangible Assets |
(29.03%) | 0.00% |
Research and Development Expense of Revenue |
0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | — |
Free Cash Flow per Share |
(778.97) | 0.00 |
Cash per Share |
3,478.06 | 0.00 |
Shareholders Equity per Share |
4,050.36 | 0.00 |
Interest Debt per Share |
0.00 | — |
Book value per Share |
4,050.36 | 0.00 |
Free Cash Flow |
(122.30) | 0.00 |
Working Capital |
511.13 | 170.70 |
Capital Expenditures |
(2.09) | 0.00 |
Net Current Asset Value |
501.15 | 170.70 |
| Other line items | ||
Quick Ratio |
11.77 | 25.35 |
Depreciation/Fixed assets |
0.16 | 0.00 |
Cash ROIC |
(10.35%) | 0.00% |
Accounts Payable Turnover |
0.00 | — |
Average Days of Payables |
0.00 | 0.00 |
Revenue per Share |
0.00 | — |
Operating CF per Share |
(765.67) | 0.00 |
Capex per Share |
(13.30) | 0.00 |
Average Payables |
4.77 | — |
Average Assets |
435.37 | — |
Average Common Equity |
(287.61) | — |
Capex to Sales |
0.00 | 0.00 |
Columns are period end dates · fundamentals updated 6 Nov 2026